<DOC>
	<DOCNO>NCT00979745</DOCNO>
	<brief_summary>Afamelanotide man-made drug study use preventative medication EPP sufferer . It synthetically produce analogue human alpha melanocyte stimulate hormone ( alpha-MSH ) yet available market . The purpose study look whether afamelanotide reduce number severity EPP symptoms patient exposed light . This study also look drug tolerate take people EPP . The study involve use implant , come form small rod ( approximately 2 cm x 0.15 cm ) administer skin . The implant may contain study drug afamelanotide placebo ( inactive medication ) . Over 450 subject treat afamelanotide date serious safety concern identify . For study , afamelanotide formulate controlled release depot injection ( implant ) . This mean afamelanotide release slowly body day . Once insert , implant remain body afamelanotide release slowly dissolve . This study help provide information afamelanotide . This information use determine safety efficacy ( ability drug produce effect ) drug EPP sufferer . Up 70 people participate study study sit across Europe .</brief_summary>
	<brief_title>Phase III Confirmatory Study Erythropoietic Protoporphyria ( EPP )</brief_title>
	<detailed_description>PURPOSE : To determine whether afamelanotide reduce severity phototoxic reaction patient EPP . THEORETICAL FRAMEWORK : EPP genetic photosensitivity disorder mainstay management cover sunlight , systemic beta carotene use control course UVR treatment . One mechanisms protective effect UVR treatment increase melanin content skin . UVR treatment cause DNA damage skin cell increase risk skin cancer , hence unwise use recur basis . Afamelanotide , ability stimulate melanin production without cause DNA damage associate UVR treatment , appear promising agent combat distress disorder . STUDY DESIGN : This phase III , randomise , placebo control study evaluate safety efficacy subcutaneous implant afamelanotide patient suffer EPP . The study perform compliance Good Clinical Practice ( GCP ) include archive essential document . METHODOLOGY : The target population consist male female participant . Up 70 patient diagnose EPP ( past case history ) fulfil necessary inclusion/exclusion criterion enrol . Potential study patient identify centre 's record patient well characterised history ( documented diagnosis ) EPP . Patients enrol receive afamelanotide ( 16 mg implant ) placebo accord follow dosing regime : - Group A administer active implant Days 0 , 60 , 120 , 180 240 . - Group B administer placebo implant Days 0 , 60 , 120 , 180 240 .</detailed_description>
	<mesh_term>Protoporphyria , Erythropoietic</mesh_term>
	<mesh_term>alpha-MSH</mesh_term>
	<criteria>Male female subject diagnosis EPP ( confirm elevate free protoporphyrin peripheral erythrocyte ) sufficient severity request treatment alleviate symptom . Aged 18 70 year ( inclusive ) Written informed consent prior performance studyspecific procedure . Any allergy afamelanotide polymer contain implant lignocaine local anaesthetic use administration study medication . EPP patient significant hepatic involvement . Personal history melanoma dysplastic nevus syndrome . Current Bowen 's disease , basal cell carcinoma , squamous cell carcinoma , malignant premalignant skin lesion . Any photodermatosis PLE , DLE solar urticaria . Any evidence clinically significant organ dysfunction clinically significant deviation normal clinical laboratory determination . Acute history drug alcohol abuse ( last 12 month ) . Patient assess suitable study opinion Investigator ( e.g . noncompliance history , allergic local anaesthetic , faint give injection give blood ) . Female pregnant ( confirm positive serum Î²HCG pregnancy test prior baseline ) lactating . Females childbearing potential ( premenopausal , surgically sterile ) use adequate contraceptive measure ( i.e . oral contraceptive , diaphragm plus spermicide , intrauterine device ) . Sexually active men partner child bear potential use barrier contraception trial period three month thereafter . Participation clinical trial investigational agent within 30 day prior screen visit . Prior concomitant therapy medication may interfere objective study , include drug cause photosensitivity skin pigmentation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Erythropoietic Protoporphyria</keyword>
	<keyword>EPP</keyword>
	<keyword>Afamelanotide</keyword>
</DOC>